- Home
- RAPT vs EPRX Comparison
RAPT vs EPRX Comparison
Compare RAPT & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- EPRX
- Stock Information
- Founded
- RAPT 2015
- EPRX 2011
- Country
- RAPT United States
- EPRX Canada
- Employees
- RAPT N/A
- EPRX N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- EPRX
- Sector
- RAPT Health Care
- EPRX
- Exchange
- RAPT Nasdaq
- EPRX NYSE
- Market Cap
- RAPT 122.9M
- EPRX 137.7M
- IPO Year
- RAPT 2019
- EPRX N/A
- Fundamental
- Price
- RAPT $13.31
- EPRX $5.49
- Analyst Decision
- RAPT Buy
- EPRX Strong Buy
- Analyst Count
- RAPT 5
- EPRX 2
- Target Price
- RAPT $36.75
- EPRX $11.50
- AVG Volume (30 Days)
- RAPT 133.4K
- EPRX 12.9K
- Earning Date
- RAPT 08-07-2025
- EPRX 08-07-2025
- Dividend Yield
- RAPT N/A
- EPRX N/A
- EPS Growth
- RAPT N/A
- EPRX N/A
- EPS
- RAPT N/A
- EPRX N/A
- Revenue
- RAPT N/A
- EPRX N/A
- Revenue This Year
- RAPT N/A
- EPRX N/A
- Revenue Next Year
- RAPT N/A
- EPRX N/A
- P/E Ratio
- RAPT N/A
- EPRX N/A
- Revenue Growth
- RAPT N/A
- EPRX N/A
- 52 Week Low
- RAPT $5.67
- EPRX $2.20
- 52 Week High
- RAPT $27.84
- EPRX $6.20
- Technical
- Relative Strength Index (RSI)
- RAPT 69.39
- EPRX N/A
- Support Level
- RAPT $10.00
- EPRX N/A
- Resistance Level
- RAPT $14.09
- EPRX N/A
- Average True Range (ATR)
- RAPT 1.04
- EPRX 0.00
- MACD
- RAPT 0.42
- EPRX 0.00
- Stochastic Oscillator
- RAPT 87.32
- EPRX 0.00
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.